Header image

Boehringer Ingelheim - Sponsored Evening Symposium: Overview of the current and future treatments in interstitial lung disease*

Saturday, March 22, 2025
6:00 PM - 7:30 PM
Hall A
Sponsored By:
Boehringer Ingelheim

Details

Boehringer Ingelheim aims for this informative session to explore the evolving landscape of interstitial lung disease (ILD). The suggested topic and agenda on this symposium will focus on providing an update on the current treatment landscape in ILD, highlighting the unmet clinical needs and future ILD treatments that may address these gaps. * This session is sponsored by Boehringer Ingelheim, but developed independently by TSANZ.


Speaker

Agenda Item Image
Dr Gary "Matt" Hunninghake
Associate Professor of Medicine
Brigham and Women's Hospital

The here and now: Current treatments in ILD and unmet clinical needs

6:05 PM - 6:30 PM

Biography

Matt is a pulmonologist, genetic epidemiologist, associate director for the Center for Pulmonary Functional Imaging, and the director of the Interstitial Lung Disease Program at the Brigham and Women's Hospital. He completed medical school at the University of Iowa, residency and chief residency at Virginia Commonwealth University, and a pulmonary fellowship and a Master’s of Public Health at Harvard where he is now an Associate Professor of Medicine. In addition, to caring for patient’s in the Intensive Care Unit, and in the Interstitial Lung Disease Clinic his research has been focused on identifying the factors that will help to diagnose early stages of pulmonary fibrosis. The overarching goal of this work is to target specific groups most likely to progress to pulmonary fibrosis with the hope preventing the more advanced stages of this incurable disease. He is the Principal Investigator or co-Principal Investigator on 3 R01 grants as well as the site-PI on numerous pharmaceutical sponsored clinical trials. This work has helped to change our understanding of early stages of pulmonary fibrosis and has led to the first international guidelines for the recommendation on reporting and following patients with evidence for early stages of this disease. His grants have focused on three main themes including 1) defining the phenotype and risk factors that best help to predict early stages of pulmonary fibrosis and their progression, 2) genetic, genomic, and proteomic analyses that help to demonstrate the most important genes, and pathways associated with early pulmonary fibrosis development, and 3) screening studies to identify early-stage pulmonary fibrosis in families. Dr. Hunninghake’s ultimate goal is to consider targeted interventional efforts to reduce the progression of early stages of pulmonary fibrosis.
Agenda Item Image
Dr John Mackintosh
Respiratory and Lung Transplant Physician
The Prince Charles Hospital

What does the future hold: Future treatments in ILD

6:30 PM - 7:00 PM

Biography

Dr John Mackintosh is a respiratory and lung transplant physician at The Prince Charles Hospital, Brisbane. John provides a dedicated interstitial lung disease outpatient service and is cochair of the Queensland Statewide Interstitial Lung Disease Multi-Disciplinary Meeting that provides diagnostic and management advice to physicians across Australia.
All Speakers

Panel discussion

7:00 PM - 7:30 PM

Biography

Agenda Item Image
Assoc Prof Yet Hong Khor
Research Fellow / Respiratory And Sleep Physician
Monash University / Austin Health

Chairperson

Biography

Yet Khor is an NHMRC emerging leadership fellow at Monash University and an interstitial lung disease specialist at Austin and Alfred Health. She is the chair of TSANZ Clinical Care and Resources Sub-Committee.
loading